ECCMID 26th (2016)

Drupal spam blocked by CleanTalk.
Title Content type
A single-centre survey of invasive mould disease due to azole-resistant Aspergillus fumigatus in patients with haematological malignancies (click for details)
The safety and single-dose pharmacokinetics of CD101IV: results from a phase 1, dose-escalation study (click for details)
Screening with serum galactomannan (sGM) in haematological patients on micafungin prophylaxis: does the test remain useful for diagnosis of invasive aspergillosis? (click for details)
Human natural killer cells and Aspergillus fumigatus differentially influence their gene expression profile (click for details)
Intra-subject variability and exposure-response relationship of isavuconazole in the phase 3 SECURE study in patients with invasive mould disease caused by Aspergillus spp. and other filamentous fungi (click for details)
Invasive aspergillosis in liver disease patients: no easy way out (click for details)
Azole resistant Aspergillus fumigatus in Denmark: a laboratory based study on resistance mechanisms and genotypes (click for details)
In vitro activity of isavuconazole against azole-resistant environmental Aspergillus fumigatus isolates, cryptic Candida strains and emerging yeasts (click for details)
Assessment of serum (1,3)-beta-D-glucan and galactomannan kinetics in a retrospective study in haematological patients with invasive aspergillosis (click for details)
Aspergillus-specific and mucorales-specific PCR testing in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary mould infection (click for details)


Subscribe to ECCMID 26th (2016)